18/04/2019 18:47:30

APRIL 22 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Akorn, Inc. – AKRX

NEW YORK, April 18, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Akorn, Inc. (NASDAQ: AKRX) from August 1, 2018 through January 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Akorn investors under the federal securities laws.  If you wish to serve as lead plaintiff, you must move the Court no later than April 22, 2019.

To join the Akorn class action, go to https://pawarlawgroup.com/cases/akorn-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Akorn’s management misled investors concerning the severity of Akorn’s manufacturing violations at its Decatur, Illinois facility; (2) Akorn’s responses to the Food and Drug Administration’s (“FDA”) Form 483—which  contained a list of observations made by the FDA during its inspection of Akorn’s Decatur, Illinois facility in April and May 2018—would be deemed inadequate by the FDA; (3) Akorn repeatedly failed to correct manufacturing violations at this facility; (4) the foregoing would subject Akorn to heightened regulatory scrutiny by the FDA; and (5) as a result, Akorn’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

No class has been certified.  Until a class is certified, you are not represented by counsel unless you hire one.  You may hire counsel of your choice.  You may also do nothing at this time and be an absent member of the class.  Your ability to share in any future recovery is not dependent upon being a lead plaintiff. 

Pawar Law Group represents investors from around the world. Attorney Advertising. Prior results do not guarantee a similar outcome. 

-------------------------------

Contact:  

Vik Pawar, Esq.  

Pawar Law Group  

20 Vesey Street, Suite 1210  

New York, NY 10007  

Tel: (917) 261-2277  

Fax: (212) 571-0938  

info@pawarlawgroup.com  

Pawar-Law-Group-logo-gold.png

Related content
26 Aug - 
Akorn Receives FDA Approval for Azelastine Hydrochlorid..
01 Aug - 
Akorn Provides Preliminary Second Quarter 2019 Results
11 Jul - 
Akorn to Report Second Quarter 2019 Financial Results a..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
UPDATE - Yoko Ono and John Lennon Educational Tour Bus “Imagine A City With No Gun Violence!”
2
Translate Bio Announces Pricing of Public Offering of Common Stock
3
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SAExploration Holdings, Inc. - SAEX
4
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Pluralsight, Inc. - PS
5
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

Related stock quotes

Akorn Inc 3.690 -0.5% Stock price decreasing

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 September 2019 17:22:06
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190829.2 - EUROWEB2 - 2019-09-18 18:22:06 - 2019-09-18 17:22:06 - 1000 - Website: OKAY